stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

MannKind Corporation

United States · NASDAQ: MNKD · Market cap: · P/E: · P/S:

MannKind makes and sells an inhaled insulin product called Afrezza and is developing other inhaled medicines for serious lung and heart diseases.

MannKind is a small biopharmaceutical company with one product on the market and a pipeline of experimental drugs behind it. Its main seller is Afrezza, an insulin that diabetes patients breathe into their lungs instead of injecting. That is the whole commercial business today: a fast-acting mealtime insulin delivered through a small inhaler, aimed at people with diabetes who dislike needles or want insulin to work more quickly.

MannKind Corporation (MNKD) Furoscix: line art illustration of Furoscix on-body infusor: a small square wearable patch worn on the abdomen with a thin tube
Furoscix infusor
Furoscix delivers a diuretic through a wearable patch instead of an IV.

The company's bigger bet is a technology platform it calls Technosphere — tiny particles that can carry drugs deep into the lungs. MannKind is using it to develop inhaled versions of medicines for pulmonary hypertension and heart failure, conditions where getting a drug straight to the lungs and heart could work better than a pill or an IV. Those programs are still in testing, so they are promises rather than products. MannKind does not market Afrezza alone. It has partnership deals in which other companies sell it in different countries, and it earns money from product sales plus royalties and milestone payments from those partners. The economics are tough: Afrezza has been on the market for years without becoming a blockbuster, and the company has a history of losses and tight finances. The stock is essentially a bet on whether the pipeline pays off.


The founding story is unusual. Alfred Mann, a prolific inventor and billionaire, started the company and spent decades and a fortune of his own money trying to make inhaled insulin work after early versions failed. That persistence kept MannKind alive through near-death moments, but it also shows the risk: a single-product company whose future depends on new drugs clearing expensive clinical trials.

Saved answer · last researched 16 Nov 2026